Cargando…

Comparing treatment and outcomes in advanced esophageal, gastroesophageal junction, and gastric adenocarcinomas: a population-based study

BACKGROUND: Treatment of advanced or metastatic esophageal adenocarcinoma (EAC) follows the guidelines for gastroesophageal junction adenocarcinoma (GEJC) and gastric adenocarcinoma (GAC), but patients with EAC are often excluded from clinical studies of GEJC/GAC. OBJECTIVES: Here we describe treatm...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pape, Marieke, Vissers, Pauline A. J., Dijksterhuis, Willemieke P. M., Bertwistle, David, McDonald, Laura, Mostert, Bianca, Derks, Sarah, Oving, Irma M., Verhoeven, Rob H. A., van Laarhoven, Hanneke W. M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2023
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10031599/ https://www.ncbi.nlm.nih.gov/pubmed/36970109 http://dx.doi.org/10.1177/17588359231162576

Ejemplares similares

A population-based study in resected esophageal or gastroesophageal junction cancer aligned with CheckMate 577
por: Pape, Marieke, et al.
Publicado: (2022)

Population-based study of treatment and outcome of recurrent oesophageal or junctional cancer
por: Pape, Marieke, et al.
Publicado: (2022)

A population-based study in synchronous versus metachronous metastatic esophagogastric adenocarcinoma
por: Pape, Marieke, et al.
Publicado: (2022)

Gender Differences in Treatment Allocation and Survival of Advanced Gastroesophageal Cancer: A Population-Based Study
por: Dijksterhuis, Willemieke P M, et al.
Publicado: (2021)

Treatment patterns and survival in advanced unresectable esophageal squamous cell cancer: A population‐based study
por: Pape, Marieke, et al.
Publicado: (2022)

Increased assessment of HER2 in metastatic gastroesophageal cancer patients: a nationwide population-based cohort study
por: Dijksterhuis, Willemieke P. M., et al.
Publicado: (2020)

Preoperative Chemoradiotherapy Versus Perioperative Chemotherapy for Patients With Resectable Esophageal or Gastroesophageal Junction Adenocarcinoma
por: Anderegg, M. C. J., et al.
Publicado: (2017)

A population-based comparison of patients with metastatic esophagogastric carcinoma between Japan and the Netherlands
por: Pape, Marieke, et al.
Publicado: (2023)

Long-term health-related quality of life in patients with advanced esophagogastric cancer receiving first-line systemic therapy
por: Pape, Marieke, et al.
Publicado: (2023)

Genomic similarity between gastroesophageal junction and esophageal Barrett's adenocarcinomas
por: Ferrer-Torres, Daysha, et al.
Publicado: (2016)

The success of anti-PD-1 with chemotherapy for esophageal squamous cell carcinoma
por: van Laarhoven, Hanneke W.M., et al.
Publicado: (2023)

A Comparison of Real-World Treatment Patterns and Clinical Outcomes in Patients Receiving First-Line Therapy for Unresectable Advanced Gastric or Gastroesophageal Junction Cancer Versus Esophageal Adenocarcinomas
por: Shankaran, Veena, et al.
Publicado: (2020)

Evolving Management Strategies for Metastatic Esophageal and Gastroesophageal Junction Adenocarcinoma
por: Das, Satya, et al.
Publicado: (2018)

Can we do without chemotherapy? A perspective on the combinations nivolumab-chemotherapy and nivolumab–ipilimumab in metastatic gastric and esophageal cancer
por: Derks, Sarah, et al.
Publicado: (2022)

Emerging targets in gastroesophageal adenocarcinoma: what the future looks like
por: Petrillo, Angelica, et al.
Publicado: (2023)

SOURCE beyond first‐line: A survival prediction model for patients with metastatic esophagogastric adenocarcinoma after failure of first‐line palliative systemic therapy
por: Kuijper, Steven C., et al.
Publicado: (2022)

The Impact of Signet Ring Cell Differentiation on Outcome in Patients with Esophageal and Gastroesophageal Junction Adenocarcinoma
por: van Hootegem, Sander J. M., et al.
Publicado: (2019)

Understanding the Challenges Faced by Esophageal and Gastroesophageal Junction Cancer Survivors
por: McGillivray, Erin, et al.
Publicado: (2023)

AI-assisted discovery of an ethnicity-influenced driver of cell transformation in esophageal and gastroesophageal junction adenocarcinomas
por: Ghosh, Pradipta, et al.
Publicado: (2022)

Heterogeneity of first‐line palliative systemic treatment in synchronous metastatic esophagogastric cancer patients: A real‐world evidence study
por: Dijksterhuis, Willemieke P.M., et al.
Publicado: (2019)

Maspin differential expression patterns as a potential marker for targeted screening of esophageal adenocarcinoma/gastroesophageal junction adenocarcinoma
por: Dzinic, Sijana H., et al.
Publicado: (2019)

Trends in surgical techniques for the treatment of esophageal and gastroesophageal junction cancer: the 2022 update
por: de Groot, E M, et al.
Publicado: (2023)

Impact of Radiation Dose on Postoperative Complications in Esophageal and Gastroesophageal Junction Cancers
por: Kastelowitz, Noah, et al.
Publicado: (2021)

Gastroesophageal junction adenocarcinoma metastasizing to gingiva
por: Masamatti, Smita S, et al.
Publicado: (2013)

Epidemiology of Gastroesophageal Junction Adenocarcinoma in Korea
por: Kim, Jin-Jo
Publicado: (2018)

Isolated Splenic Metastases of Her2+++ Gastroesophageal Junction Adenocarcinoma
por: Sigrand, Julie, et al.
Publicado: (2016)

Neoadjuvant chemotherapy in older patients with gastric cancer undergoing surgery: a population-based cohort study
por: Keywani, Kammy, et al.
Publicado: (2023)

Neoadjuvant Treatment Strategies for Resectable Proximal Gastric, Gastroesophageal Junction and Distal Esophageal Cancer
por: Ahmad, M. Usman, et al.
Publicado: (2022)

Real-World Outcomes and Factors Associated With the Second-Line Treatment of Patients With Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma
por: Barzi, Afsaneh, et al.
Publicado: (2019)

Independent Stage Classification for Gastroesophageal Junction Adenocarcinoma
por: Hirata, Yuki, et al.
Publicado: (2023)

Association between body composition, survival, and toxicity in advanced esophagogastric cancer patients receiving palliative chemotherapy
por: Dijksterhuis, Willemieke P.M., et al.
Publicado: (2019)

Pembrolizumab for first-line treatment of advanced unresectable or metastatic esophageal or gastroesophageal junction cancer
por: Hirose, Toshiharu, et al.
Publicado: (2023)

Anastomotic Leaks following Esophagectomy for Esophageal and Gastroesophageal Junction Cancer: The Key Is the Multidisciplinary Management
por: Ortigão, Raquel, et al.
Publicado: (2021)

Gastroesophageal junction adenocarcinoma 1-year after sleeve gastrectomy
por: Brown, Kevin C, et al.
Publicado: (2023)

SPOTlight on GLOW
por: Derks, Sarah, et al.
Publicado: (2023)

Circulating tumor DNA predicts outcome in metastatic gastroesophageal cancer
por: van Velzen, Merel J. M., et al.
Publicado: (2022)

HER2 gene amplification in esophageal squamous cell carcinoma is less than in gastroesophageal junction and gastric adenocarcinoma
por: HUANG, JUN-XING, et al.
Publicado: (2013)

Relevance of Position and Movement of the Gastroesophageal Junction in Gastroesophageal Reflux Disease
por: Lee, Yeong Yeh
Publicado: (2013)

Long-Term Survival in Gastroesophageal Junction Adenocarcinoma: Ramucirumab
por: Gil-Delgado, Maria Angeles, et al.
Publicado: (2018)

Treatment for metastatic adenocarcinoma of the stomach and gastroesophageal junction: 2020
por: Hsu, Andrew, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_u8lmkremg0ul5fkq4dm69u7gb1